The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.
Each year for the past 12 years, Novartis employees have been giving back to the breast cancer community.
Kenyan Community Health Education Meetings & Health Camps Supported Through Novartis Canada International Volunteer Program
Novartis heart failure treatment PrEntresto™ (sacubitril/valsartan) now covered by the Régie de l'assurance maladie du Québec (RAMQ)*
Optimal use of Novartis heart failure treatment (Pr)Entresto™ could save more than 3,000 lives in Canada each year according to a new analysis1
Novartis employees return from volunteer healthcare mission in rural Kenya
Canadians with advanced skin cancer share their disease journey with launch of an empowering photo series: Melanoma Through My Lens
Health Canada approves oral treatment (Pr)AFINITOR® (everolimus) for progressive, non-functional GI and lung neuroendocrine tumours (NET)
This is an Amended Media Release further to Novartis Pharmaceuticals Canada Inc.’s (“Novartis”) Media Release issued on January 7, 2015 for Fluad Pediatric®.
FLAME study evaluating efficacy of Ultibro® Breezhaler® to reduce chronic COPD exacerbations published in NEJM
(Pr)JADENU(TM) (deferasirox) for the management of chronic iron overload is now available in Canada
This site is intended for an audience in Canada.